These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31492601)

  • 1. Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice.
    Pinto Tasende JA; Maceiras Pan FJ; Mosquera Martínez JA; Fernández Dominguez L; Correa Rey B; García Porrúa C
    Reumatol Clin (Engl Ed); 2021 Apr; 17(4):203-206. PubMed ID: 31492601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.
    Alegre-Sancho JJ; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; Pedraz-Penalva T; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martinez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Sivera F
    Front Med (Lausanne); 2023; 10():1294247. PubMed ID: 38053615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
    Ramonda R; Lorenzin M; Carriero A; Chimenti MS; Scarpa R; Marchesoni A; Lubrano di Scorpaniello E; Salvarani C; Cauli A; Semeraro A; Santo L; Ortolan A; Doria A; Fracassi E; Virelli G; Masia M; Fanizzi R; Visalli E; Amato G; Carletto A; Foti R;
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33593933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.
    Ogdie A; Gladman DD; Coates LC; Pournara E; Parikh B; Mease PJ
    Rheumatol Ther; 2023 Aug; 10(4):849-860. PubMed ID: 37148474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population.
    Berman J; Furer V; Berman M; Isakov O; Zisman D; Haddad A; Elkayam O
    Biologics; 2021; 15():463-470. PubMed ID: 34819720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
    Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis.
    Klavdianou K; Lazarini A; Grivas A; Tseronis D; Tsalapaki C; Rapsomaniki P; Antonatou K; Thomas K; Boumpas D; Katsimbri P; Vassilopoulos D
    Front Med (Lausanne); 2020; 7():288. PubMed ID: 32637422
    [No Abstract]   [Full Text] [Related]  

  • 9. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
    Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
    Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab for the treatment of psoriatic arthritis.
    Baronaite Hansen R; Kavanaugh A
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.
    Chimenti MS; Fonti GL; Conigliaro P; Sunzini F; Scrivo R; Navarini L; Triggianese P; Peluso G; Scolieri P; Caccavale R; Picchianti Diamanti A; De Martino E; Salemi S; Birra D; Altobelli A; Paroli M; Bruzzese V; Laganà B; Gremese E; Conti F; Afeltra A; Perricone R
    Expert Opin Biol Ther; 2020 Jul; 20(7):813-821. PubMed ID: 32401062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB; Mease PJ; Schett G; Kirkham B; Strand V; Williams N; Fox T; Pricop L; Jugl SM; Gandhi KK;
    Arthritis Res Ther; 2018 Jun; 20(1):113. PubMed ID: 29880010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.
    van der Heijde D; Landewé RB; Mease PJ; McInnes IB; Conaghan PG; Pricop L; Ligozio G; Richards HB; Mpofu S
    Arthritis Rheumatol; 2016 Aug; 68(8):1914-21. PubMed ID: 27014997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab: A New Treatment Option for Psoriatic Arthritis.
    Mease P; McInnes IB
    Rheumatol Ther; 2016 Jun; 3(1):5-29. PubMed ID: 27747518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
    Nash P; McInnes IB; Mease PJ; Thom H; Hunger M; Karabis A; Gandhi K; Mpofu S; Jugl SM
    Rheumatol Ther; 2018 Jun; 5(1):99-122. PubMed ID: 29605841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab.
    Kiltz U; Sfikakis PP; Gaffney K; Bounas A; Gullick N; Lespessailles E; Brandt-Juergens J; Rashkov R; Schulz B; Pournara E; Jagiello P
    Rheumatol Ther; 2022 Aug; 9(4):1129-1142. PubMed ID: 35674938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.